FAP and myocardial ischemia: A FAP-targeting CAR-M incorporating an anti-FAP scFv and the intracellular signaling domain CD147 was administered intravenously after cardiac ischemia–reperfusion (I/R) in mice, with echocardiographic improvements in left ventricular ejection fraction (LVEF) and fractional shortening (FS), reduced fibroblast numbers in the infarct area, and no observed cardiac toxicity (87).